Recombinant Activated Factor VII in Children Undergoing Cardiac Surgery: Remember How and Why to Use It
نویسندگان
چکیده
منابع مشابه
The role of recombinant activated factor VII in cardiac surgery
Recombinant factor VIIa may reduce surgical blood loss and transfusion of blood products in cardiac surgery. However, the true risks of its use in this setting remains to be elucidated, especially when it is administered with other potent pro-haemostatic agents. We reviewed the recent literature on this topic and suggest that the off label use of recombinant factor VIIa is likely to continue. I...
متن کاملUse of recombinant factor VII in cardiac surgery.
The off-label use of recombinant human coagulation factor VIIa has been increasing to a number of different treatment areas since its original approval in 1999. Several US patents describe claims for FVIIa utilization in nonhemophilia patients, treatment of bleeding due to trauma, as a means to reverse major bleeding, including intracranial bleeding, induced from fibrinolytic therapy as well as...
متن کاملSalvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery
BACKGROUND Refractory post cardiopulmonary bypass (CPB) bleeding continues to cause concern for cardiac surgeons and intensivists. Massive postoperative hemorrhage following CPB is multifactorial and not fully understood, and it is also associated with increased mortality and morbidity. Activated recombinant factor VII (rFVIIa) has emerged as possible salvage medication in refractory post cardi...
متن کاملComprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery.
BACKGROUND This observational study sought to identify the off-label use pattern of recombinant activated factor VII (rFVIIa) in cardiac surgery and to identify predictors of its effectiveness and risk. METHODS AND RESULTS At 18 Canadian centers, 522 nonhemophiliac cardiac surgical patients received rFVIIa during the period 2003 through 2006; data were available, and retrospectively collected...
متن کاملFactor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery.
OBJECTIVE Postcardiopulmonary bypass hemorrhage remains a serious complication of cardiac surgery. Given concerns regarding adverse effects of blood product transfusion and limited efficacy of current antifibrinolytics, procoagulant medications, including recombinant factor VIIa (rFVIIa) and factor eight inhibitor bypass activity (FEIBA), increasingly have been used in managing refractory bleed...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cardiothoracic and Vascular Anesthesia
سال: 2019
ISSN: 1053-0770
DOI: 10.1053/j.jvca.2019.01.052